Nanoparticle technologies for cancer therapy
Handbook of Experimental Pharmacology, ISSN: 0171-2004, Vol: 197, Issue: 197, Page: 55-86
2010
- 350Citations
- 440Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations350
- Citation Indexes349
- 349
- CrossRef241
- Patent Family Citations1
- Patent Families1
- Captures440
- Readers440
- 365
- 75
- Mentions1
- Blog Mentions1
- Blog1
Most Recent Blog
Drug-Loaded Polymeric Nanoparticles for Cancer Stem Cell Targeting
Introduction Recent studies have suggested that, the growth of tumors is similar to that of normal proliferative tissues, fueled by limited numbers of dedicated stem cells that are capable of self-renewal, called cancer stem cells (CSCs) (Reya et al., 2001; Clarke et al., 2006; Adams and Strasser, 2008; Dick, 2009; Wilson et al., 2009; He et al., 2016). Quite a lot of efforts have been put into th
Book Chapter Description
Nanoparticles as drug delivery systems enable unique approaches for cancer treatment. Over the last two decades, a large number of nanoparticle delivery systems have been developed for cancer therapy, including organic and inorganic materials. Many liposomal, polymer-drug conjugates, and micellar formulations are part of the state of the art in the clinics, and an even greater number of nanoparticle platforms are currently in the preclinical stages of development. More recently developed nanoparticles are demonstrating the potential sophistication of these delivery systems by incorporating multifunctional capabilities and targeting strategies in an effort to increase the efficacy of these systems against the most difficult cancer challenges, including drug resistance and metastatic disease. In this chapter, we will review the available preclinical and clinical nanoparticle technology platforms and their impact for cancer therapy. © 2009 Springer-Verlag Berlin Heidelberg.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=77953235193&origin=inward; http://dx.doi.org/10.1007/978-3-642-00477-3_2; http://www.ncbi.nlm.nih.gov/pubmed/20217526; http://link.springer.com/10.1007/978-3-642-00477-3_2; https://doi.org/10.1007%2F978-3-642-00477-3_2; https://dx.doi.org/10.1007/978-3-642-00477-3_2; https://link.springer.com/chapter/10.1007/978-3-642-00477-3_2
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know